Skip to main content
. 2022 Mar 31;13:846248. doi: 10.3389/fimmu.2022.846248

Figure 2.

Figure 2

SARS-CoV-2 neutralizing antibody levels in healthy controls and RMD patients receiving different types of vaccines. HC, healthy controls. (A) a vs. BBIBP-CorV (1 m) (p <0.0001), b vs. Gam-COVID-Vac (1 m) (p <0.0001), c vs. AZD1222 (1 m) (p <0.0001), d vs. BBIBP-CorV (4 m) (p = 0.0106), e vs. BNT162b2 (1 m) (p <0.0001). (B) a vs. BBIBP-CorV (1 m) (p = 0.0122), b vs. BBIBP-CorV (4 m) (p = 0.0107), c vs. AZD1222 (4 m) (p = 0.0107), d vs. AZD1222 (1 m) (p = 0.0179), e vs. BNT162b2 (1 m) (p = 0.0298).